ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Myeloma in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Cancer
Leukemia
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Charlotte, NC, USA:

A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma

this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple...

Active, not recruiting
Refractory Multiple Myeloma
Relapsed Multiple Myeloma
Drug: ION251

Phase 1

Ionis Pharmaceuticals
Ionis Pharmaceuticals

Charlotte, North Carolina, United States and 5 other locations

and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...

Enrolling
Multiple Myeloma
Biological: bb2121
Drug: Talquetamab

Phase 2

Celgene
Celgene

Charlotte, North Carolina, United States and 25 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Lenalidomide

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Charlotte, North Carolina, United States and 145 other locations

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and pre...

Enrolling
Multiple Myeloma
Drug: NMS-03597812
Drug: NMS-03597812 + dexamethasone

Phase 1

Nerviano Medical Sciences

Charlotte, North Carolina, United States and 5 other locations

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma...

Enrolling
Multiple Myeloma
Myeloma
Drug: Bendamustine
Drug: FT576 (Allogenic CAR NK cells with BCMA expression)

Phase 1

Fate Therapeutics
Fate Therapeutics

Charlotte, North Carolina, United States and 13 other locations

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab
Drug: Bortezomib

Phase 2

AbbVie
AbbVie

Charlotte, North Carolina, United States and 40 other locations

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...

Active, not recruiting
Multiple Myeloma
Drug: TNB-383B

Phase 1, Phase 2

TeneoOne

Charlotte, North Carolina, United States and 13 other locations

(CAR) T Cells, in participants with relapsed and/or refractory multiple myeloma.The study will consist of 2 parts: dose-escalation ...

Active, not recruiting
Multiple Myeloma
Biological: CC-98633

Phase 1

Juno Therapeutics

Charlotte, North Carolina, United States and 10 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Charlotte, North Carolina, United States and 211 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Fludarabine
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Charlotte, North Carolina, United States and 126 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems